Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.
Dupilumab improves atopic dermatitis severity in adolescents, adults with skin of color | Image Credit: © this_baker - © this_baker - stock.adobe.com.
Among a study population of adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis (AD) and skin of color, dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) demonstrated positive outcomes that improved overall disease severity, itch, and reduced post-inflammatory hyperpigmentation, according to an announcement from Regeneron. These data were announced at the 2025 Revolutionizing Atopic Dermatitis (RAD) conference in Nashville, Tennessee, on June 7.1
Via the DISCOVER phase 4, single-arm, open-label trial, the data are the first clinical trial results for dupilumab in a large population of patients with darker skin tones. The trial featured 120 patients with AD and skin of color. Of the participants, 82% were Black, 11% Asian, 2% American Indian/Alaska Native, and 5% Arab, Central American, or other. Individuals were treated every 2 weeks with dupilumab using a weight-based dosing regimen.
Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), the trial's primary endpoint. In some patients, results were observed as early as 2 weeks. Additionally, 53% of participants achieved a clinically meaningful improvement in itch, defined as a 4-point or more reduction on the peak-pruritus numerical rating scale. Similar to EASI-75 results, some patients achieved itch improvement as early as 2 weeks.
Overall, patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, decreasing from 5.1 points to 2.4 points (moderate/marked to mild). Score changes were based on the clinician-reported Post-Inflammatory Hyperpigmentation Severity Scale (0-8).1,2
Compared to 78% of individuals who were "very or extremely bothered" by dry skin at baseline, 18% were bothered at 24 weeks, based on patient reporting, stated Regeneron.
"Atopic dermatitis, a chronic disease with underlying type 2 inflammation, has a high prevalence and quality of life impact on patients with skin of color," said Andrew Alexis, MD, MPH, in a statement. Alexis is a professor of Clinical Dermatology at Weill Cornell Medicine. "The results from the DISCOVER trial showed that [dupilumab] patients with atopic dermatitis and darker skin not only experienced reduced disease severity and itch but also saw improvements in areas of particular concern, including dyspigmentation and dry skin," Alexis added. "These data deepen the clinical understanding of atopic dermatitis within this underserved population, including use of newly validated scales.”
In the United States, dupilumab is approved for the following indications, according to Regeneron and Sanofi1,2:
References:
1. Dupixent (dupilumab) data at Revolutionizing Atopic Dermatitis (RAD) Conference reinforce use in atopic dermatitis patients with skin of color. Regeneron. Press release. June 7, 2025. Accessed June 9, 2025. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-data-revolutionizing-atopic-dermatitis-rad
2. Media Update: RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color. Sanofi. Press release. June 7, 2025. Accessed June 9, 2025. https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-07-22-30-00-3095548
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.